Liraglutide's 21-day daily subcutaneous injection pharmacokinetics, glucose, and insulin effects investigated in clinical trial

Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of liraglutide, a GLP-1 receptor agonist, is crucial for optimizing its therapeutic use, particularly in conditions involving glucose dysregulation and insulin resistance. While liraglutide is established for Type 2 Diabetes and obesity, detailed data on its sustained daily administration over several weeks, specifically regarding its blood levels and precise impact on glucose and insulin dynamics, helps refine dosing strategies and predict long-term efficacy and safety. This trial addresses a gap in understanding the full PK/PD profile over a consistent 3-week regimen.

This Phase 1 clinical trial investigated the effects of liraglutide administered via daily subcutaneous (SC) injections for 21 days in human subjects. The study design included a comparator arm receiving placebo injections. Primary endpoints focused on assessing the blood concentration of liraglutide (pharmacokinetics) and its subsequent effects on glucose and insulin levels (pharmacodynamics). Additionally, the trial observed the overall safety and tolerability of the liraglutide regimen throughout the 3-week period.